12 active not recruiting, 10 completed, 9 terminated, 3 recruiting. 39 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Active not recruiting 12, Completed 10, Terminated 9, Recruiting 3, Unknown 3, Withdrawn 2 |
| Phase 1 | 8 | Active not recruiting 2, Completed 2, Terminated 2, Unknown 2 |
Follow Metastatic Prostate Carcinoma: new trials by email Literature Review of Metastatic Prostate Carcinoma trials Research Report on Metastatic Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration - Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 38 | 2025-08-27 | 2026-03-25 |
| Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review - Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 210 | 2024-07-09 | 2026-10-07 |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial Antiandrogen Therapy, Bone Scan, Computed Tomography - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2024-02-18 | 2026-10-08 |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-09-26 | 2024-03-07 | |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer 68Ga-PSMA-11, Positron Emission Tomography (PET) - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Thomas Hope | 15 | 2021-09-28 | 2026-05-15 |
| 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 22 | 2021-06-16 | 2022-10-21 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-08-19 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer Antiandrogen Therapy, Abiraterone Acetate, Prednisone - Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | University of Washington | 10 | 2020-06-29 | 2023-10-26 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 7 | 2020-05-11 | 2026-07-15 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Abiraterone Acetate, Enzalutamide, Erdafitinib - Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma | Phase 2 | Terminated | University of Washington | 3 | 2020-04-27 | 2023-09-28 |
| ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 10 | 2019-11-13 | 2024-07-16 |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Abiraterone Acetate, Apalutamide, Prednisone - Metastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 60 | 2019-07-22 | 2026-10-07 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Berzosertib, Carboplatin, Docetaxel - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2019-05-29 | 2026-10-09 |
| Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Completed | University of Utah | 17 | 2018-10-02 | 2024-11-29 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 937 | 2018-04-02 | 2021-09-30 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Emory University | 17 | 2018-02-22 | 2025-07-17 |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2018-01-30 | 2023-05-01 |
Showing 20 of 39. Sign in to see all of them.
Prostatic Neoplasms (39) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Lymphadenopathy (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Genital Diseases (39) · Genital Diseases, Male (39) · Genital Neoplasms, Male (39) · Male Urogenital Diseases (39) · Neoplasms (39) · Neoplasms by Site (39) · Prostatic Diseases (39) · Urogenital Diseases (39) · Urogenital Neoplasms (39) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adnexal Diseases (1) · Breast Diseases (1) · Digestive System Diseases (1)
Abiraterone Acetate (8) · Magnetic Resonance Spectroscopy (8) · Prednisone (8) · Carboplatin (7) · deltacortene (6) · Docetaxel (5) · prednylidene (5) · Radiation (4) · Radiotherapy (4) · XRP6258 (4) · apalutamide (4) · cabazitaxel (4) · enzalutamide (4) · gallium 68 PSMA-11 (4) · 68Ga-DKFZ-PSMA-11 (3)
M.D. Anderson Cancer Center (7) · University of Washington (5) · Jonsson Comprehensive Cancer Center (3) · National Cancer Institute (NCI) (3) · Barbara Ann Karmanos Cancer Institute (2) · Mamta Parikh (2) · Northwestern University (2) · OHSU Knight Cancer Institute (2) · City of Hope Medical Center (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · Seattle Institute for Biomedical and Clinical Research (1)
United States (36) · China (2)
Ana Aparicio (2) · Paul Corn (2) · Robert Montgomery (2) · A P Chen (1) · Atish D Choudhury (1) · Aung Naing (1) · Channing Paller, MD (1) · Chong-Xian Pan (1) · David VanderWeele, MD, PhD (1) · Dingwei Ye, M.D. (1) · Douglas G McNeel, MD PhD (1) · Eleni Efstathiou (1) · Elisabeth Heath, M.D. (1) · Elisabeth I. Heath (1) · Gregory C Ravizzini, MD (1)
PMID 29876010, PMID 30700328, PMID 31515154, PMID 33602654, PMID 35241087, PMID 35277461, PMID 36256912, PMID 36898948, PMID 39076107, PMID 39227508, PMID 39420060, PMID 39503807, PMID 40139261, PMID 41378786, PMID 41646361, PMID 41698328
P30CA015704 (4), P50CA097186 (4), P30CA022453 (2), P30CA093373 (2), P30CA006973 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), U01CA154967 (1), UM1CA186689 (1), UM1CA186709 (1)